Trimethylangelicin (TMA) is a natural derived compound studied in many FFC projects. In order to identify compounds with biological properties similar to those of TMA but with reduced or absent toxicity, new molecules had been synthesized. Now researchers would like to expand their studies on the anti-inflammatory activity of new selected TMA derivatives. The anti-inflammatory effect would be added to the corrector properties and possible double and biological effects (correction and anti-inflammation) could be a great advantage for CF therapy. To realize this project specific CF cell lines (CFBE41o- cells), stimulated with the pro-inflammatory cytokine TNF-alpha or infected with P. aeruginosa will be used, studying the effects of TMA treatment alone and in combination with other known anti-inflammatory and antimicrobial agents. The second goal will be to characterize the best compounds with respect to its effects on the transcriptome, secretome and kinome. The expected results are to demonstrate that TMA analogues have anti-inflammatory activity in vitro and in vivo experiments, regardless of the already known correction activity. This may pave the way to discover novel anti-inflammatory drugs for CF lung disease.